Association between VNTR Polymorphism in Promoter Region of Prodynorphin (PDYN) Gene and Methamphetamine Dependence
DOI:
https://doi.org/10.3889/oamjms.2015.079Keywords:
Methamphetamine dependence, PDYN, Polymorphism, VNTR, SusceptibilityAbstract
AIM: Prodynorphin (PDYN; OMIM: 131340) is the precursor of the dynorphin related peptides which plays an important role in drug abuse. Previous studies have been shown that the expression of PDYN is regulated by a genetic polymorphism of VNTR in the promoter region of the gene.
MATERIALS AND METHODS: The present case-control study was performed on 52 (41 males, 11 females) methamphetamine dependence patients and 635 (525 males, 110 females) healthy blood donors frequency matched with the patients according to age and gender, as a control group was participated in the study.
RESULTS: The genotypes of VNTR PDYN polymorphism were determined using PCR method. The HL (OR = 1.22, 95%CI: 0.67-2.20, P = 0.500) and LL (OR = 0.86, 95%CI: 0.28-2.57, P = 0.792) genotypes does not alter the risk of methamphetamine dependence, in comparison with the HH genotypes.
CONCLUSION: The present study revealed no association between the VNTR polymorphism in the promoter region of the PDYN gene and methamphetamine dependence risk.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Schwarzer C. 30 years of dynorphins - new insights on their functions in neuropsychiatric diseases. Pharmacol Therapeut. 2009; 123:353-370. DOI: https://doi.org/10.1016/j.pharmthera.2009.05.006
Yuferov V, Ji F, Nielsen DA, Levran O, Ho A, Morgello S, Shi R, Ott J, Kreek MJ. A functional haplotype implicated in vulnerability to develop cocaine dependence is associated with reduced PDYN expression in human brain. Neuropsychopharmacology. 2009; 34:1185-1197. DOI: https://doi.org/10.1038/npp.2008.187
Wittmann W, Schunk E, Rosskothen I, Gaburro S, Singewald N, Herzog H, Schwarzer C. Prodynorphin-derived peptides are critical modulators of anxiety and regulate neurochemistry and corticosterone. Neuropsychopharmacology. 2009; 34:775-785. DOI: https://doi.org/10.1038/npp.2008.142
Knoll AT, Carlezon WA Jr. Dynorphin, stress, and depression. Brain Res. 2010; 1314:56–73. DOI: https://doi.org/10.1016/j.brainres.2009.09.074
Butelman ER, Yuferov V, Kreek MJ. κ-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction. Trends Neurosci. 2012; 35:587-596. DOI: https://doi.org/10.1016/j.tins.2012.05.005
Zimprich A, Kraus J, Woltje M, Mayer P, Rauch E, Höllt V. Allelic variation in the human prodynorphin gene promoter alters stimulus-induced expression. J Neurochem. 2000; 74:472-477. DOI: https://doi.org/10.1046/j.1471-4159.2000.740472.x
Saify K, Saadat I, Saadat M. Association between VNTR polymorphism in promoter region of prodynorphin (PDYN) gene and heroin dependence. Psychiatry Res. 2014; 219:690-692. DOI: https://doi.org/10.1016/j.psychres.2014.06.048
Rouault M, Nielsen DA, Ho A, Kreek MJ, Yuferov V. Cell-specific effects of variants of the 68-base pair tandem repeat on prodynorphin gene promoter activity. Addict Biol. 2011; 16:334-346. DOI: https://doi.org/10.1111/j.1369-1600.2010.00248.x
Wei SG, Zhu YS, Lai JH, Xue HX, Chai ZQ, Li SB. Association between heroin dependence and prodynorphin gene polymorphisms. Brain Res Bull. 2011; 85:238-242. DOI: https://doi.org/10.1016/j.brainresbull.2011.02.010
Chen AC, LaForge KS, Ho A, McHugh PF, Kellogg S, Bell K, Schluger RP, Leal SM, Kreek MJ. Potentially functional polymorphism in the promoter region of prodynorphin gene may be associated with protection against cocaine dependence or abuse. Am J Med Genet. 2002; 114:429-435. DOI: https://doi.org/10.1002/ajmg.10362
Ray R, Doyle GA, Crowley JJ, Buono RJ, Oslin DW, Patkar AA, Mannelli P, DeMaria PA Jr, O’Brien CP, Berrettini WH. A functional prodynorphin promoter polymorphism and opioid dependence. Psychiatry Genet. 2005; 15:295-298. DOI: https://doi.org/10.1097/00041444-200512000-00013
Williams TJ, LaForge KS, Gordon D, Bart G, Kellogg S, Ott J, Kreek MJ. Prodynorphin gene promoter repeat associated with cocaine/alcohol codependence. Addict Biol. 2007; 12:496-502. DOI: https://doi.org/10.1111/j.1369-1600.2007.00069.x
Nomura A, Ujike H, Tanaka Y, Otani K, Morita Y, Kishimoto M, Morio A, Harano M, Inada T, Yamada M, Komiyama T, Sekine Y, Iwata N, Sora I, Iyo M, Ozaki N, Kuroda S. Genetic variant of prodynorphin gene is risk factor for methamphetamine dependence. Neurosci Lett. 2006; 400:158-162. DOI: https://doi.org/10.1016/j.neulet.2006.02.038
Levran O, Yuferov V, Kreek MJ. The genetics of the opioid system and specific drug addictions. Hum Genet. 2012; 131:823-842. DOI: https://doi.org/10.1007/s00439-012-1172-4
Khalighinasab MR, Saify K, Saadat M. Association between GSTM1 and GSTT1 genetic polymorphisms and susceptibility to methamphetamine dependence. Mol Biol Res Commun. 2015; 4:25-32.
Rafiee, L, Saadat I, Saadat M. Glutathione S-transferase genetic polymorphisms (GSTM1, GSTT1 and GSTO2) in three Iranian populations. Mol Biol Rep. 2010; 37:155-158. DOI: https://doi.org/10.1007/s11033-009-9565-8
Saadat M. Distribution of ACE insertion/deletion (I/D) polymorphism in Iranian populations. Mol Biol Res Commun. 2015; 4:63-66.
Fallahzadeh-Abarghooei L, Zahedi T, Mirabedi F, Saadat M. Allelic prevalence of intron 3 insertion/deletion genetic polymorphism of DNA double-strand break repair gene XRCC4 in four healthy Iranian populations. Egypt J Med Hum Genet. 2015; 16: 215-218. DOI: https://doi.org/10.1016/j.ejmhg.2015.02.004
Saadat M, Ansari-Lari M. Polymorphism of XRCC1 (at codon 399) and susceptibility to breast cancer, a meta-analysis of the literatures. Breast Cancer Res Treat. 2009; 115:137-144. DOI: https://doi.org/10.1007/s10549-008-0051-0
Downloads
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0